To evaluate 12-month outcomes following fluocinolone acetonide (FAc 0.2 μg/day) implant in pseudophakic patients with diabetic macular edema (DME) that persists or recurs despite previous treatment with anti-vascular endothelial growth factors (anti-VEGF) and dexamethasone implant (DEX) in a UAE population.
Methods:
A retrospective, observational, single-center, 12-month audit study, where 22 pseudophakic eyes (22 patients) with DME were treated with the FAc intravitreal implant according to licensed UAE indications. Outcome measurements at baseline and at months 1, 3, 6, and 12 included best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP).
Results:
Post-FAc implantation, mean BCVA significantly improved at 1, 3, and 12 months (+10.4 ± 16.1, +22.8 ± 13.6, and +25.5 ± 13.0 letters, respectively; p < 0.0001), with 86% of eyes gaining ⩾15 letters at month 12. Similarly, CMT reduced significantly at month 1, and stabilized thereafter at months 3–12 (−171.5 ± 72.5 µm, −240.9 ± 74.2 µm, and −246.2 ± 93.4 µm, respectively; p < 0.0001). By month 12, 64% (n = 14/22) of eyes had a CMT below 300 µm. Only 1 eye had an IOP ⩾ 21 mmHg at baseline and month 12. Five eyes required IOP lowering drops and 1 required IOP-lowering surgical intervention.
Conclusion:
In pseudophakic patients with DME FAc implant provide a substantial functional and anatomical benefits for up to 12 months.
BrowningDJStewartMWLeeC.Diabetic macular edema: evidence-based management. Indian J Ophthalmol2018; 66(12): 1736–1750.
3.
HaritoglouCMaierMNeubauerAS, et al. Current concepts of pharmacotherapy of diabetic macular edema. Expert Opin Pharmacother2020; 20: 1–9.
4.
KhooKManREKReesG, et al. The relationship between diabetic retinopathy and psychosocial functioning: a systematic review. Qual Life Res2019; 28(8): 2017–2039.
5.
GonderJRWalkerVMBarbeauM, et al. Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY). J Ophthalmol2014; 2014: 939315.
GonzalezVHCampbellJHolekampNM, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol2016; 172: 72–79.
8.
BresslerSBAyalaARBresslerNM, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol2016; 134(3): 278–285.
9.
BresslerNMBeaulieuWTGlassmanAR, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol2018; 136(3): 257–269.
10.
AugustinAJBoppSFechnerM, et al. Three-year results from the Retro-IDEAL study: real-world data from diabetic macular edema (DME) patients treated with ILUVIEN® (0.19 mg fluocinolone acetonide implant). Eur J Ophthalmol2020; 30(2): 382–391.
11.
EichenbaumDABuznegoCWengCY, et al. When and how to incorporate steroids for persistent diabetic macular edema: a discussion of real-world treatment optimization strategies. Ophthalmic Surg Lasers Imaging Retina2018; 49(7): S5–S15.
BaileyCChakravarthyULoteryA, et al. Real-world experience with 0.2 mg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond)2017; 31(12): 1707–1715.
16.
EatonAKohSSJimenezJ, et al. The USER study: a chart review of patients receiving a 0.2 microg/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther2019; 8(1): 51–62.
17.
ChakravarthyUTaylorSRKochFHJ, et al. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol2018; 103: 1072–1077.
18.
RehakMBuschCUnterlauftJD, et al. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Acta Diabetol2020; 57(4): 469–478.
19.
Vaz-PereiraSCastro-de-SousaJPMartinsD, et al. The outcomes of switching from short- to long-term intravitreal corticosteroid implant therapy in patients with diabetic macular edema. Ophthalmic Res2020; 63(2): 114–121.
CampochiaroPABrownDMPearsonA, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology2011; 118(4): 626–635.e2.
22.
CampochiaroPABrownDMPearsonA, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology2012; 119(10): 2125–2132.
23.
CoelhoJMalheiroLMelo BeirãoJ, et al. Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes. Clin Ophthalmol2019; 13: 1751–1759.
24.
MenezoMRocaMMenezoV, et al. Intravitreal dexamethasone implant Ozurdex in the treatment of diabetic macular edema in patients not previously treated with any intravitreal drug: a prospective 12-month follow-up study. Curr Med Res Opin2019; 19: 1–6.
25.
Pareja-RíosARuiz-delaFuente-RodríguezPBonaque-GonzálezS, et al. Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmol2018; 11(1): 77–82.
26.
AlfaqawiFLipPLElsherbinyS, et al. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye (Lond)2017; 31(4): 650–656.
27.
FigueiraJHenriquesJAmaroM, et al. A nonrandomized, open-label, multicenter, Phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res2017; 57(3): 166–172.
28.
YangYBaileyCLoewensteinA, et al. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina2015; 35(12): 2440–2449.
